Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 19/20 | 1.00 |
| ▸ | BTK | Q06187 | 1/20 | 0.67 |
| ▸ | ITK | Q08881 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5585427 | 0.95 | EGFR (1.00) | EGFRBTK | |
| SCHEMBL19360700 | 0.92 | EGFR (0.86) | EGFRBTKITK | |
| SCHEMBL19360702 | 0.92 | EGFR (0.88) | EGFRBTKITK | |
| SCHEMBL9923765 | 0.90 | EGFR (0.82) | EGFRBTKITK | |
| SCHEMBL2718163 | 0.90 | EGFR (1.00) | EGFRBTKITK | |
| SCHEMBL9925293 | 0.90 | EGFR (0.81) | EGFRBTKITK | |
| SCHEMBL5585132 | 0.89 | EGFR (1.00) | EGFRBTKITK | |
| SCHEMBL5585465 | 0.87 | EGFR (1.00) | EGFR | |
| SCHEMBL9893779 | 0.87 | EGFR (1.00) | EGFRITK | |
| SCHEMBL9923761 | 0.85 | EGFR (0.83) | EGFRBTKITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10081606-B2 | Heteroaryl compounds and uses thereof | CELGENE CAR LLC (BM) | 2018-09-25 | — | — | US | disclosed |
| US-20180072687-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2018-03-15 | — | — | US | disclosed |
| US-20180072687-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2018-03-15 | — | — | US | disclosed |
| US-20180072687-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2018-03-15 | — | — | US | disclosed |
| US-9765038-B2 | Heteroaryl compounds and uses thereof | CELGENE CAR LLC (BM) | 2017-09-19 | — | — | US | disclosed |
| US-9765038-B2 | Heteroaryl compounds and uses thereof | CELGENE CAR LLC (BM) | 2017-09-19 | — | — | US | disclosed |
| US-9765038-B2 | Heteroaryl compounds and uses thereof | CELGENE CAR LLC (BM) | 2017-09-19 | — | — | US | disclosed |
| EP-2635285-B1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RES INC (US) | 2017-05-03 | — | — | EP | disclosed |
| EP-2635285-B1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RES INC (US) | 2017-05-03 | — | — | EP | disclosed |
| US-20160130236-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2016-05-12 | — | — | US | disclosed |
| US-20160130236-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2016-05-12 | — | — | US | disclosed |
| US-20160130236-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2016-05-12 | — | — | US | disclosed |
| US-9238629-B2 | Heteroaryl compounds and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-01-19 | — | — | US | disclosed |
| US-9238629-B2 | Heteroaryl compounds and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-01-19 | — | — | US | disclosed |
| US-9238629-B2 | Heteroaryl compounds and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-01-19 | — | — | US | disclosed |
| US-20120149722-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149722-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149722-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| WO-2012061303-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072687-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | EGFR 1981/4885BTK 594/4885ITK 2697/4885 |
| US-20160130236-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | EGFR 1981/4885BTK 594/4885ITK 2697/4885 |
| US-20120149722-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | EGFR 1981/4885BTK 594/4885ITK 2697/4885 |
| US-10081606-B2 | Heteroaryl compounds and uses thereof | ABCG2, CYP3A43, CYP3A5 | EGFR 1981/4885BTK 594/4885ITK 2697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.